Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice

Wencheng Liu, Lingzhi Zhao, Brittany Blackman, Mayur Parmar, Man Ying Wong, Thomas Woo, Fangmin Yu, Dolan Sondhi, Stephen M. Kaminsky, Ronald Crystal, Steven M. Paul

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Passive immunization with anti-tau monoclonal antibodies has been shown by several laboratories to reduce age-dependent tau pathology and neurodegeneration in mutant tau transgenic mice. These studies have used repeated high weekly doses of various tau antibodies administered systemically for several months and have reported reduced tau pathology of ~40–50% in various brain regions. Here we show that direct intrahippocampal administration of the adeno-associated virus (AAV)-vectored anti-phospho-tau antibody PHF1 to P301S tau transgenic mice results in high and durable antibody expression, primarily in neurons. Hippocampal antibody levels achieved after AAV delivery were ~50-fold more than those reported following repeated systemic administration. In contrast to systemic passive immunization, we observed markedly reduced (≥80–90%) hippocampal insoluble pathological tau species and neurofibrillary tangles following a single dose of AAV-vectored PHF1 compared with mice treated with an AAV-IgG control vector. Moreover, the hippocampal atrophy observed in untreated P301S mice was fully rescued by treatment with the AAV-vectored PHF1 antibody. Vectored passive immunotherapy with an anti-tau monoclonal antibody may represent a viable therapeutic strategy for treating or preventing such tauopathies as frontotemporal dementia, progressive supranuclear palsy, or Alzheimer’s disease.

Original languageEnglish
Pages (from-to)12425-12435
Number of pages11
JournalJournal of Neuroscience
Volume36
Issue number49
DOIs
Publication statusPublished - 7 Dec 2016
Externally publishedYes

Keywords

  • AAV vector
  • Alzheimer’s disease
  • Anti-tau antibody
  • Passive immunization
  • PHF-tau
  • Tauopathy

ASJC Scopus subject areas

  • Neuroscience(all)

Fingerprint Dive into the research topics of 'Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice'. Together they form a unique fingerprint.

  • Cite this

    Liu, W., Zhao, L., Blackman, B., Parmar, M., Wong, M. Y., Woo, T., Yu, F., Sondhi, D., Kaminsky, S. M., Crystal, R., & Paul, S. M. (2016). Vectored intracerebral immunization with the anti-tau monoclonal antibody PHF1 markedly reduces tau pathology in mutant tau transgenic mice. Journal of Neuroscience, 36(49), 12425-12435. https://doi.org/10.1523/JNEUROSCI.2016-16.2016